Investor Relations


Investor Relations


PPD is dedicated to helping customers deliver life-changing therapies to patients by bending the cost and time curve of drug development and optimizing value. Committed to global operational excellence, we deploy a comprehensive suite of solutions, generating evidence to demonstrate effectiveness, safety and value. Passionate about improving health, we are defined by our people, more than 30,000 strong, whose talent, ingenuity and commitment are our formula for customer satisfaction.

Leveraging patient-centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, a novel approach to site and patient access, and comprehensive lab services via PPD® Laboratories. We serve pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships, functional service partnerships and PPD® Biotech, for biotech and small to midsize pharma companies.

In an increasingly complex research landscape, biopharmaceutical leaders can depend on PPD for quality performance, continual innovation and trusted partnership.

PPD: Dedicated to helping deliver life-changing therapies
PPD Inc.

Annual Report

Investor Contact

Tracy Krumme
Vice President, Head of Investor Relations
+1 910 558 4186

News Releases

PPD Common Stock

  • Price
  • Change
  • Today's High

Data Provided by Refinitiv. Minimum 15 minutes delayed.